Snyder's Model -- de Sitter Special Relativity Duality and de Sitter Gravity

Between Snyder's quantized space-time model in de Sitter space of momenta and the \dS special relativity on \dS-spacetime of radius $R$ with Beltrami coordinates, there is a one-to-one dual correspondence supported by a minimum uncertainty-like argument. Together with Planck length $\ell_P$, $R\simeq (3/\Lambda)^{1/2}$ should be a fundamental constant. They lead to a dimensionless constant $g{\sim\ell_PR^{-1}}=(G\hbar c^{-3}\Lambda/3)^{1/2}\sim 10^{-61}$. These indicate that physics at these two scales should be dual to each other and there is in-between gravity of local \dS-invariance characterized by $g$. A simple model of \dS-gravity with a gauge-like action on umbilical manifolds may show these characters. It can pass the observation tests and support the duality.Comment: 32 page

Newton-Hooke Limit of Beltrami-de Sitter Spacetime, Principles of Galilei-Hooke's Relativity and Postulate on Newton-Hooke Universal Time

Based on the Beltrami-de Sitter spacetime, we present the Newton-Hooke model under the Newton-Hooke contraction of the $BdS$ spacetime with respect to the transformation group, algebra and geometry. It is shown that in Newton-Hooke space-time, there are inertial-type coordinate systems and inertial-type observers, which move along straight lines with uniform velocity. And they are invariant under the Newton-Hooke group. In order to determine uniquely the Newton-Hooke limit, we propose the Galilei-Hooke's relativity principle as well as the postulate on Newton-Hooke universal time. All results are readily extended to the Newton-Hooke model as a contraction of Beltrami-anti-de Sitter spacetime with negative cosmological constant.Comment: 25 pages, 3 figures; some misprints correcte

Constraining neutrino mass in dynamical dark energy cosmologies with the logarithm parametrization and the oscillating parametrization

We constrain two dynamical dark energy models that are parametrized by the logarithm form of $w(z)=w_{0}+w_{1}\left(\frac{\ln (2+z)}{1+z}-\ln 2\right)$ and the oscillating form of $w(z)=w_{0}+w_{1}\left(\frac{\sin(1+z)}{1+z}-\sin(1)\right)$. Comparing with the Chevallier-Polarski-Linder (CPL) model, the two parametrizations for dark energy can explore the whole evolution history of the universe properly. Using the current mainstream observational data including the cosmic microwave background data and the baryon acoustic oscillation data as well as the type Ia supernovae data, we perform the $\chi^2$ statistic analysis to global fit these models, finding that the logarithm parametrization and the oscillating parametrization are almost as well as the CPL scenario in fitting these data. We make a comparison for the impacts of the dynamical dark energy on the cosmological constraints on the total mass of active neutrinos. We find that the dark energy properties could significantly change the fitting results of neutrino mass. Looser constraints on $\sum m_{\nu}$ are obtained in the logarithm and oscillating models than those derived in the CPL model. Consideration of the possible mass ordering of neutrinos reveals that the most stringent constraint on $\sum m_{\nu}$ appears in the degenerate hierarchy case

Upregulation of Endogenous HMOX1 Expression by a Computer-Designed Artificial Transcription Factor

Heme oxygenase-1 (HO-1) is well known as a cytoprotective factor. Research has revealed that it is a promising therapeutic target for cardiovascular diseases. In the current study, an HMOX1 (HO-1 gene) enhancer-specific artificial zinc-finger protein (AZP) was designed using bioinformatical methods. Then, an artificial transcription factor (ATF) was constructed based on the AZP. In the ATF, the p65 functional domain was used as the effector domain (ED), and a nuclear localization sequence (NLS) was also included. We next analyzed the affinity of the ATF to the HMOX1 enhancer and the effect of the ATF on endogenous HMOX1 expression. The results suggest that the ATF could effectively upregulate endogenous HMOX1 expression in ECV304 cells. With further research, the ATF could be developed as a potential drug for cardiovascular diseases